Table 3. Number of deaths (%), total number of patients, and crude and adjusted OR for death among immunosuppressed patients, patients with specific diseases or conditions (cancer [solid organ or haematologic], solid organ transplant or systemic autoimmune diseases), and patients receiving immune suppressive treatments prior to admission (systemic steroids, biological treatments, or immunosuppressors).
All analyses have use non-immunosuppressed patients as reference category.
| Deaths: n (%) | N | OR (95% CI) | aOR* (95% CI) | p* | |
|---|---|---|---|---|---|
| Non-IS | 2143 (19.3) | 11095 | 1 | 1 | |
| IS | 661 (31.3) | 2111 | 1.90 (1.72–2.11) | 1.60 (1.43–1.79) | <0.001 |
| Patients with specific diseases and conditions | |||||
| All cancers (SO and H) | 465 (33.3) | 1398 | 2.08 (1.81–2.38) | 1.59 (1.38–1.82) | <0.001 |
| SO cancer | 343 (31.7) | 1081 | 1.94 (1.66–2.27) | 1.39 (1.18–1.63) | <0.001 |
| SO cancer with MT | 84 (30.4) | 276 | 1.82 (1.37–2.43) | 1.87 (1.33–2.63) | <0.001 |
| SO cancer, no MT | 259 (32.2) | 805 | 1.98 (1.63–2.41) | 1.27 (1.05–1.54) | 0.013 |
| Hematologic cancer | 139 (38.8) | 358 | 2.42 (1.92–3.05) | 2.31 (1.76–3.03) | <0.001 |
| Leukaemia | 66 (39.3) | 168 | 2.70 (1.89–3.84) | 2.20 (1.49–3.25) | <0.001 |
| Lymphoma | 77 (40.0) | 194 | 2.75 (2.16–3.51) | 2.94 (2.19–3.95) | <0.001 |
| Transplant | 57 (34.3) | 166 | 2.18 (1.60–2.99) | 3.12 (2.23–4.36) | <0.001 |
| Patients receiving immune suppressive treatments prior to admission | |||||
| Systemic steroids | 202 (35.4) | 570 | 2.29 (1.96–2.68) | 2.16 (1.80–2.61) | <0.001 |
| Biological treatment | 49 (26.8) | 183 | 1.52 (1.06–2.19) | 1.97 (1.33–2.91) | 0.001 |
| Immunosuppressors** | 109 (27.7) | 394 | 1.59 (1.27–1.99) | 2.06 (1.64–2.60) | <0.001 |
Non-IS: non-immunosuppressed patients. IS: immunosuppressed patients. SAID: systemic autoimmune diseases. OR: crude odds ratio. CI: confidence interval. aOR: adjusted odds ratio. SO: solid organ. H: haematological. MT: metastases.
*Adjusted for age, sex, level of dependency, smoking status, and comorbidities (arterial hypertension, chronic heart failure, chronic obstructive bronchopulmonary disease, asthma, dementia, moderate-severe chronic liver disease, moderate-severe chronic renal failure, and diabetes mellitus).
**Immunosuppressors include: azathioprine, methotrexate, tacrolimus, cyclophosphamide, mycophenolate, cyclosporin, rapamycin, and everolimus.